Altre lingue Palisade Bio, Inc.

Azioni

SNCA

US6963894026

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 19/04/2024			Variaz. 5gg	Var. 1 gen.
4,71 ^USD	-7,10%		+14,32%	-46,78%

16/04	Palisade Bio dimostra con successo la bioattivazione di PALI-2108 nello studio ex-vivo di pazienti normali sani e con colite ulcerosa? Feci	CI
26/03	Palisade Bio, Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 in Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients Stool	17/04
Sector Update: Health Care Stocks Edge Up Tuesday Afternoon	16/04
Palisade Bio Shows Bioactivation of PALI-2108 in Study; Shares Rise	16/04
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool	16/04
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients? Stool	16/04
Palisade Bio to Participate in the Virtual Investor Lunch Break Event	11/04
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™	10/04
Palisade Bio Announces 1-for-15 Reverse Stock Split	03/04
North American Morning Briefing : Stocks Seen -2-	02/04
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update	27/03
Palisade Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Palisade Bio, Inc. Announces Resignation of Mary Ann Gray as Member of the Board	06/03
Palisade Bio to Present at Digestive Disease Week (DDW) 2024	15/02
Palisade Bio Names Donald Williams as Chairman	13/02
Palisade Bio Provides Corporate Update and Reiterates Guidance	13/02
Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members	08/02
Palisade Bio, Inc. Announces Advisory Board Appointments	08/02
Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders	08/02
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million	30/01
MÄRKTE USA/Fester - Neue Rekordhochs dank sinkender Anleihezinsen	29/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Palisade Bio, Inc.

Azioni

SNCA

US6963894026

Altre lingue

Filtri